Oncolytic intralesional therapy for metastatic melanoma

In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therap...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2024-08, Vol.41 (4), p.457-460
Main Authors: DePalo, Danielle K, Perez, Matthew C., Huibers, Anne, Olofsson Bagge, Roger, Zager, Jonathan S.
Format: Article
Language:English
Subjects:
Antitumor agents
Biomedical and Life Sciences
Biomedicine
Cancer and Oncology
Cancer och onkologi
Cancer Research
Cancer therapies
Genetic modification
Hematology
Herpes viruses
Humans
Immunotherapy
Injections, Intralesional
Intralesional
Lysis
Medical prognosis
Melanoma
Melanoma - pathology
Melanoma - therapy
Metastases
Metastasis
Metastatic melanoma
Neoplasm Metastasis
Oncology
Oncolysis
oncolytic viral therapy intranist disease
Oncolytic Virotherapy - methods
Oncolytic Viruses - physiology
Regional chemotherapy
Regionally metastatic melanoma
Response rates
Review
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Surgical Oncology
Tumor cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therapies are one category of non-surgical treatment options available for ITM. They induce tumor cell lysis and systemic anti-tumor activity through selective infection of tumor cells by naturally occurring or genetically modified factors. While there are numerous oncolytic viral therapies in various stages of development for the treatment of ITM, this discussion focuses on the mechanism and available literature for the two most established herpes virus-based therapies.
ISSN:0262-0898
1573-7276
1573-7276
DOI:10.1007/s10585-023-10228-4